Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CorMedix Inc. stock logo
CRMD
CorMedix
$5.24
-1.7%
$4.18
$2.57
$7.00
$287.20M1.86543,659 shs17,129 shs
ERGO
Entia Biosciences
$0.00
$0.00
$0.00
N/AN/AN/AN/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CorMedix Inc. stock logo
CRMD
CorMedix
-2.20%-2.02%+30.64%+64.51%+13.89%
ERGO
Entia Biosciences
0.00%0.00%0.00%0.00%-50.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CorMedix Inc. stock logo
CRMD
CorMedix
1.4658 of 5 stars
3.50.00.00.02.91.70.6
ERGO
Entia Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CorMedix Inc. stock logo
CRMD
CorMedix
3.00
Buy$13.00148.09% Upside
ERGO
Entia Biosciences
N/AN/AN/AN/A

Current Analyst Ratings

Latest CRMD, MDG1, and ERGO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/9/2024
CorMedix Inc. stock logo
CRMD
CorMedix
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$19.00
4/9/2024
CorMedix Inc. stock logo
CRMD
CorMedix
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
3/13/2024
CorMedix Inc. stock logo
CRMD
CorMedix
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$10.00 ➝ $9.00
1/31/2024
CorMedix Inc. stock logo
CRMD
CorMedix
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$18.00 ➝ $14.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CorMedix Inc. stock logo
CRMD
CorMedix
$60K4,786.74N/AN/A$1.28 per share4.09
ERGO
Entia Biosciences
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CorMedix Inc. stock logo
CRMD
CorMedix
-$46.34M-$0.92N/AN/AN/AN/A-72.31%-63.97%5/20/2024 (Estimated)
ERGO
Entia Biosciences
N/AN/A0.00N/AN/AN/AN/AN/AN/A

Latest CRMD, MDG1, and ERGO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/12/2024Q4 2023
CorMedix Inc. stock logo
CRMD
CorMedix
-$0.21-$0.26-$0.05-$0.26N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CorMedix Inc. stock logo
CRMD
CorMedix
N/AN/AN/AN/AN/A
ERGO
Entia Biosciences
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CorMedix Inc. stock logo
CRMD
CorMedix
N/A
6.97
6.78
ERGO
Entia Biosciences
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
CorMedix Inc. stock logo
CRMD
CorMedix
34.18%
ERGO
Entia Biosciences
N/A

Insider Ownership

CompanyInsider Ownership
CorMedix Inc. stock logo
CRMD
CorMedix
3.60%
ERGO
Entia Biosciences
28.30%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
CorMedix Inc. stock logo
CRMD
CorMedix
8254.81 million52.84 millionOptionable
ERGO
Entia Biosciences
6N/AN/ANot Optionable

CRMD, MDG1, and ERGO Headlines

SourceHeadline
Hdfc ErgoHdfc Ergo
moneycontrol.com - April 23 at 3:57 PM
Digital Health Spotlight: Entia looks to improve cancer care at homeDigital Health Spotlight: Entia looks to improve cancer care at home
digitalhealth.net - August 18 at 3:16 PM
Cancer monitoring platform Entia secures $20m funding boostCancer monitoring platform Entia secures $20m funding boost
news.sky.com - July 26 at 4:43 PM
Singing this song on Holy Thursday can purify your soul (and save you time in Purgatory)Singing this song on Holy Thursday can purify your soul (and save you time in Purgatory)
catholicnewsagency.com - April 7 at 4:54 PM
Top HDFC ERGO Health Insurance PlansTop HDFC ERGO Health Insurance Plans
forbes.com - April 6 at 11:05 PM
Cooler Master Hybrid 1 Ergo Gaming Chair ReviewCooler Master Hybrid 1 Ergo Gaming Chair Review
ign.com - February 26 at 12:56 AM
Entia Biosciences, Inc. (ERGO)Entia Biosciences, Inc. (ERGO)
finance.yahoo.com - October 3 at 1:46 AM
HDFC ERGO partners with HDFC Life, to offer all-round protection to customersHDFC ERGO partners with HDFC Life, to offer all-round protection to customers
livemint.com - September 25 at 11:24 PM
Entia Biosciences Inc (ERGO)Entia Biosciences Inc (ERGO)
nasdaq.com - January 7 at 10:21 AM
Entia Biosciences Dividend Per Share (TTM)Entia Biosciences Dividend Per Share (TTM)
ycharts.com - December 26 at 8:27 PM
Entia Biosciences EPS Diluted (5 Year Growth)Entia Biosciences EPS Diluted (5 Year Growth)
ycharts.com - December 22 at 12:47 AM
Entia Biosciences Year to Date Total Returns (Daily)Entia Biosciences Year to Date Total Returns (Daily)
ycharts.com - December 20 at 7:44 PM
Medtech firm Entia raises $12m for ‘virtual oncology solution’Medtech firm Entia raises $12m for ‘virtual oncology solution’
pharmatimes.com - October 11 at 10:09 AM
BGF invests $12m in virtual oncology business EntiaBGF invests $12m in virtual oncology business Entia
angelnews.co.uk - October 11 at 10:09 AM
Entia Biosciences Inc.Entia Biosciences Inc.
barrons.com - August 29 at 10:53 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

CorMedix logo

CorMedix

NASDAQ:CRMD
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Entia Biosciences

OTCMKTS:ERGO
Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.